October 22, 2012
Bookmark and Share  
 
                 
  HCV
»
»
»
»

 

Greetings:

Below are some important mid-month updates from the HCV and HBV Websites:

1.New HCSP Baby Boomers Postcard

Baby boomers

Be sure to download and print out this important piece of information. The Baby Boomers postcard and other educational materials can be downloaded here.

2. We have recently updated our Top Ten documents that were viewed on the HCV and HBV Advocate Websites – find out what others are reading regarding viral hepatitis.

HBV

HCV

3.HCV Drug Pipeline – has been updated to include the most recent news items—including the exciting news from Abbott and Enanta about 99% cure rates with the new Quad interferon-free combination. Be sure to check out the forthcoming HCV Advocate newsletter for a detailed analysis of this important clinical trial. 

-----------------------------------

Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at www.help4hep.org  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 

.

4. Top News (Blog) from the hepatitis blog includes: 

Hepatitis C Treatment Adherence Is Important for HIV/HCV Coinfected People
October 22

Low incidence of reinfection with HCV after treatment in active drug users
October 22

High Recurrence Risk for HCC Following Pegylated IFN Alpha-2b Plus Ribavirin
October 22

Unlicensed tattoo artists worrying health district
October 20

Liver cancer patient not wasting time
October 19

Vertex Draws Collaboration Interest For Hepatitis C Combo
October 19

Enanta's Lead Hepatitis C Compound ABT-450 Advances into a Phase 3 Clinical Trial through its Collaboration with Abbott
October 17

Biotron hepatitis treatment looks promising
October 16

BioLineRx Completes Pre-Clinical Development Of BL-8020
October 15

Rapid Tests Accurate in First-Line HCV Screening
October 15

Abbott's Hepatitis C Drugs Clear Virus in 99% of Patients
October 15

Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naïve and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study
October 15

 

 and much, much more…..

 

Sincerely,

Alan

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

 
  HBV
»
»
»